Immix Biopharma, Inc.

NASDAQ:IMMX

Biotechnology

Healthcare
$7.11 +0.99%

+$0.09 today

Market cap
$595.91M
Beta
0.10
P/E (TTM)
-10.1
EPS (TTM)
-$0.91
52W Low $1.94High $11.61

Volume 0.88M

Average 1.07M

IMMX Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Immix Biopharma, Inc.NASDAQ: IMMX

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income growth accelerates

Q1 FY2026 net income of $10.09M (cash outflow) rose 122.1% year over year, ahead of the +67.3% change in trailing-twelve-month net income. Sequentially, it fell 5.6% from the prior quarter. Over 3 fiscal years it compounded at +52.9% a year.

Context

  • Net income grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 5 analysts of -$23.41M (-20.5%) for the fiscal year ending Dec 2026, a slowdown from the +36.2% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$10.09M-5.6% QoQ
Last fiscal yearDec 2025
-$29.44M+36.2% YoY
LTMMar 2026
-$34.98M+67.3% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+122.1%+1.8%-120.3 pp
1 year+36.2%-20.5%-56.7 pp
3-year CAGR+52.9%-24.8%-77.7 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(29.44M) USD
Year-over-year change
-36.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How IMMX compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +67.3% is the 3rd highest of 11, against a peer median of +31.9%.
  • Over three fiscal years its annual growth of +52.9% compares with a peer median of +7.8%.
IMMX Competitors
Net Income for IMMX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RCUSArcus Biosciences, Inc.LTM Jun 2026$460M USD+54.4%+9.8%393.2%
ABVXAbivax S.A.FY2025€322.84M EUR+83.2%+74.5%—
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$309.06M USD+37.6%+32.1%275948.2%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$294.88M USD+220.5%+13.6%42.0%
NBPNovaBridge BiosciencesLTM Sep 2025CN¥150.96M CNY-47.8%-67.2%—
IMUXImmunic, Inc.LTM Mar 2026$104.29M USD+8.2%-6.9%—
MGNXMacroGenics, Inc.LTM Mar 2026$70.36M USD+26.1%-14.6%44.8%
IMMPImmutep LimitedFY2025A$61.43M AUD+43.8%+24.0%1218.0%
CTMXCytomX Therapeutics, Inc.LTM Mar 2026$59.14M USD-242.2%-44.1%166.4%
CRDFCardiff Oncology, Inc.LTM Mar 2026$44.76M USD-8.4%+5.8%8526.1%
IMMXImmix Biopharma, Inc.LTM Mar 2026$34.98M USD+67.3%+52.9%—
Peer median (excluding IMMX) —+31.9%+7.8%393.2%

Competitors are the stored peer set for IMMX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(24.38M)(8.23M)(15.6M)(21.61M)(29.44M)
Depreciation & Amortization2.47K2.14K5.47K115.39K364.5K
Deferred Income Tax00000
Stock-Based Compensation218.98K624.07K2.57M3.02M2.44M
Change in Working Capital(391.04K)195.21K1.65M3.97M2.7M
Accounts Receivables97.67K(236.38K)(893.4K)(971.53K)2.06M
Inventory00000
Accounts Payables(106.06K)1.13M2.43M4.4M1.03M
Other Working Capital(382.64K)(700.15K)111.84K537.2K(384.74K)
Other Non-Cash Items22.96M002.94M0
Operating Cash Flow(1.59M)(7.41M)(11.37M)(14.6M)(23.93M)
Capital Expenditures(802)3(52.09K)(1.18M)(732.93K)
Acquisitions (Net)00000
Purchases of Investments0000(6.48M)
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(802)0(52.09K)(1.18M)(7.21M)
Debt Repayment200K(50K)000
Common Stock Issued18.65M3.39M15.7M15.95M107.39M
Common Stock Repurchased0(99.96K)000
Dividends Paid00000
Other Financing Activities0(6.72K)(232K)00
Financing Cash Flow18.85M3.23M15.46M15.95M107.39M
Effect of Forex Changes(5.43K)(31.52K)33.09K(3.62K)3.84K
Net Change in Cash17.25M(4.21M)4.07M172.16K76.25M
Free Cash Flow(1.59M)(7.41M)(11.42M)(15.77M)(24.66M)

Immix Biopharma, Inc.

NASDAQ:IMMX

Intrinsic Alpha fair value

Locked

Current Price

$7.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.